Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

By afschroeder • March 21, 2026

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C, Bardia A. Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. ESMO Open. 2026 Mar 19;11(4):106905. doi: 10.1016/j.esmoop.2026.106905. Epub ahead of print. PMID: 41861751.

Tags: Hematology/Oncology, HR-positive/HER2-negative metastatic breast cancer, metastatic triple-negative breast cancer, Pooled analysis, Publications, Sacituzumab govitecan, safety

Related Posts

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers

Yoon J, Chen CY, Watson R, Smyth E, Wainberg Z, Oh DY. Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. Am Soc[...]

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates

Davenport S, Xie B, Hamblett K, Hausman D, Villalobos I, Singh HP, Cobrinik D, Hoon DSB, Zhou JY, Sibug-Saber M, Ma Y, Konecny GE, Heur[...]

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]